Prescription medicine
Digoxin Brand names: Lanoxin; first approved as Lanoxin Pediatric
Digoxin (Lanoxin) is a prescription medicine with an FDA approval on record since 1954. FDA's NDC Directory lists it from 26 generic labelers, and pharmacies paid $0.133 per digoxin 125 mcg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the NDA 9330 record on Drugs@FDA; every digoxin label on DailyMed.
Highlights of the record
FDA label of December 5, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageLANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults.
Forms and strengths
- 0.0625 mg
- 0.125 mg
- 0.25 mg
- 0.05 mg/ml
- 0.25 mg/ml
Tablet; injection; injection (solution); solution.
On the market
- Earliest approval on file
- November 16, 1954 Lanoxin Pediatric, Azurity; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 15 first October 24, 1975; 9 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 30 of which 26 under generic applications, 5 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.133 per tablet Digoxin 125 mcg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 4 since 2013 1 Class I among all firms' recalls; latest March 25, 2024; 2 more by firms not listed as its makers
- FAERS reports
- 71,335 through July 30, 2026
What is digoxin used for?
From the label: indications and usageLANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults LANOXIN is indicated for the treatment of mild to moderate heart failure in adults. LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. […]
Conditions named in the indications of digoxin's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Cardiac Glycoside.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
Is there a generic for digoxin (Lanoxin)?
The FDA approved the first generic digoxin on October 24, 1975. 15 generic applications are approved; 9 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists digoxin from 26 labelers under a generic (ANDA) application and from 5 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1954 earliest approval on file
- 1975 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for digoxin (Lanoxin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.133 per Digoxin 125 mcg tablet, up 20% from $0.111 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Digoxin 125 mcg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Digoxin 0.05 mg/mL solution | Generic | $1.15 per mL | n/a | -6% |
| Digoxin 125 mcg tablet | Generic | $0.133 per tablet | $3.98 | +20% |
| Digoxin 250 mcg tablet | Generic | $0.148 per tablet | $4.45 | +2% |
| Digoxin 62.5 mcg tablet | Generic | $8.59 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $257.83 | +0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has digoxin been recalled?
The FDA's Enforcement Report lists 6 recalls naming digoxin since 2013: 1 Class I (the most serious), 3 Class II, 2 Class III; 0 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of digoxin and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 25, 2024 | Class III | Novitium Pharma LLC | Failed Impurities/Degradation Specifications |
| March 4, 2024 | Class III | Novitium Pharma LLC | Cross Contamination with Other Products:(mycophenolate mofetil). |
| August 25, 2023 | Class I | Marlex Pharmaceuticals, Inc. | Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: DIGOXIN, Tablet, 0.125 mg may have potentially been mislabeled as one of the following drugs: MELATONIN, Tablet, 3 mg, NDC 08770140813 … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: DIGOXIN, Tablet, 125 mcg may have potentially been mislabeled as the following drug: CHOLECALCIFEROL/ CALCIUM/ PHOSPHORUS, Tablet, 120 … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the digoxin label say about other medicines?
The digoxin label names 50 other medicines in its interaction, contraindication or warning sections. The labels of 48 other medicines name digoxin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acarbose | drug interactions | Acarbose, activated charcoal, albuterol, antacids, certain cancer chemotherapy or radiation therapy, cholestyramine, colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Albuterol | drug interactions | Acarbose, activated charcoal, albuterol, antacids, certain cancer chemotherapy or radiation therapy, cholestyramine, colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Alprazolam | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and reduce digoxin dose as necessary. |
| Amiodarone | drug interactions | Amiodarone; 70%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing dose by approximately 30-50% or by modifying the dosing frequency and continue monitoring. |
| Azithromycin | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and reduce digoxin dose as necessary. |
| Carvedilol | drug interactions | Carvedilol; 16%; 14%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring. |
| Cholestyramine | drug interactions | Acarbose, activated charcoal, albuterol, antacids, certain cancer chemotherapy or radiation therapy, cholestyramine, colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Colestipol | drug interactions | Acarbose, activated charcoal, albuterol, antacids, certain cancer chemotherapy or radiation therapy, cholestyramine, colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Cyclosporine | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and reduce digoxin dose as necessary. |
| Diclofenac | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and reduce digoxin dose as necessary. |
| Diltiazem | drug interactions | Diltiazem; 20%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring. |
| Dofetilide | drug interactions | Antiarrthymics; Dofetilide; Concomitant administration with digoxin was associated with a higher rate of torsades de pointes |
| Dronedarone | drug interactions | Dronedarone; NA; 150%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing dose by approximately 30-50% or by modifying the dosing frequency and continue monitoring. |
| Epinephrine | drug interactions | Sympathomimetics; Epinephrine Norepinephrine Dopamine; Can increase the risk of cardiac arrhythmias |
Every other medicine the digoxin label names
| Medicine named | Section | What the label says |
|---|---|---|
| Epoprostenol | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; … |
| Esomeprazole | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; … |
| Exenatide | drug interactions | Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide … |
| Ibuprofen | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; … |
| Indomethacin | drug interactions | Indomethacin; 40%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the … |
| Ivabradine | drug interactions | Hyperpolarization-activated cyclic nucleotide-gated channel blocker; Ivabradine; Can increase the risk of bradycardia |
| Ketoconazole | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; … |
| Lansoprazole | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; … |
| Metformin | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; … |
| Metoclopramide | drug interactions | … cholestyramine, colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Miglitol | drug interactions | … colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Mirabegron | drug interactions | Mirabegron; 29%; 27%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing … |
| Nefazodone | drug interactions | Nefazodone; 27%; 15%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing … |
| Neomycin | drug interactions | … extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Nifedipine | drug interactions | Nifedipine; 45%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing … |
| Omeprazole | drug interactions | Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole; … |
| Penicillamine | drug interactions | … kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Phenytoin | drug interactions | … meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; … |
| Propafenone | drug interactions | Propafenone; 28%; 29%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the … |
| Quinidine | drug interactions | Quinidine; NA; 54-83%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing dose by approximately 30-50% or by modifying the dosing … |
| Quinine | drug interactions | Quinine; NA; 33%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing … |
| Rabeprazole | drug interactions | Rabeprazole; 29%; 19%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the … |
| Rifampin | drug interactions | … bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; Measure serum digoxin concentrations before initiating concomitant drugs. … |
| Ritonavir | drug interactions | Ritonavir NA 86% Digoxin concentrations increased less than 50% Amiodarone 17% 40% Measure serum digoxin concentrations before initiating concomitant drugs. |
| Sotalol | drug interactions | Sotalol; Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of … |
| Spironolactone | drug interactions | Spironolactone; 25%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the … |
| Succinylcholine | drug interactions | Neuromuscular Blocking Agents; Succinylcholine; May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. |
| Sucralfate | drug interactions | … miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; Measure serum digoxin concentrations before initiating concomitant drugs. … |
| Sulfasalazine | drug interactions | … neomycin, penicillamine, phenytoin, rifampin, St. John’s Wort, sucralfate, sulfasalazine; Measure serum digoxin concentrations before initiating concomitant drugs. … |
| Telmisartan | drug interactions | Telmisartan; 20-49%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the … |
| Teriparatide | drug interactions | Parathyroid Hormone Analog Teriparatide Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. |
| Thiamine | warnings and precautions | Patients with beri beri heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly. |
| Ticagrelor | drug interactions | Ticagrelor; 31%; 28%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing … |
| Tolvaptan | drug interactions | Tolvaptan; 30%; 20%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing … |
| Trimethoprim | drug interactions | Trimethoprim; 22-28%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the … |
| Verapamil | drug interactions | Verapamil; NA; 24%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing … |
Other labels that name digoxin
- Anhydrous citric acid and magnesium oxide and sodium picosulfate
- Apalutamide
- Atorvastatin
- Benazepril and hydrochlorothiazide
- Bupivacaine and meloxicam
- Bupropion
- Calcium chloride
- Calcium gluconate
- Canagliflozin
- Candesartan and hydrochlorothiazide
- Cannabidiol
- Celecoxib
- Ceritinib
- Clarithromycin
- Clomipramine
- Cobicistat
- Colchicine
- Crizotinib
- Cytarabine
- Darifenacin
- Darunavir
- Dexlansoprazole
- Dextrose and potassium chloride
- Dibasic and monobasic
- Dicyclomine
- Elagolix
- Eliglustat
- Enzalutamide
- Erythromycin
- Esmolol
- Etodolac
- Everolimus
- Fenoprofen
- Ferric oxyhydroxide
- Flecainide
- Fosphenytoin
- Fostamatinib
- Gentamicin
- Gepotidacin
- Glecaprevir and pibrentasvir
- Glycopyrrolate
- Hydroxychloroquine
- Isavuconazonium
- Istradefylline
- Itraconazole
- Ivacaftor
- Ketorolac
- Lapatinib ditosylate
- Lasmiditan
- Ledipasvir and sofosbuvir
- Lenacapavir
- Lenalidomide
- Levalbuterol
- Lonafarnib
- Magnesium sulfate and potassium chloride and sodium sulfate
- Magnesium sulfate and potassium sulfate and sodium sulfate
- Magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients
- Mannitol
- Maribavir
- Mavorixafor
- Mefenamic acid
- Milnacipran
- Naproxen
- Octreotide
- Oxaprozin
- Pacritinib
- Palopegteriparatide
- Pantoprazole
- Paroxetine
- Perindopril
- Piroxicam
- Ponesimod
- Posaconazole
- Potassium chloride and sodium chloride
- Potassium phosphate dibasic and potassium phosphate monobasic
- Prasugrel
- Pretomanid
- Primaquine
- Propranolol
- Ramipril
- Ranolazine
- Remibrutinib
- Risperidone
- Rolapitant
- Simvastatin
- Siponimod
- Sofosbuvir and velpatasvir
- Sofosbuvir and velpatasvir and voxilaprevir
- Sotagliflozin
- Sulfamethoxazole and trimethoprim
- Tamsulosin
- Thalidomide
- Tramadol
- Trazodone
- Valbenazine
- Vandetanib
- Vemurafenib
- Vibegron
- Vilazodone
- Vonoprazan
- Zoledronic acid
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What do FAERS reports show for digoxin?
The FDA Adverse Event Reporting System holds 71,335 reports that list digoxin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 13,780 are coded as a death and 36,261 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as digoxin?
16 other medicines are given the same way (oral) and in the same FDA class as digoxin or labeled mainly for the same use (heart failure), the same class first. Heart failure lists all 37 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Carvedilol | Heart failure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Spironolactone | Heart failure | 38 labelers | $0.0426 per tablet 25 mg tablet | A presentation being discontinued |
| Hydrochlorothiazide | Heart failure | 44 labelers | $0.0115 per tablet 25 mg tablet | A presentation being discontinued |
| Furosemide | Heart failure | 33 labelers | $0.026 per tablet 20 mg tablet | In shortage |
| Sacubitril and valsartan | Heart failure | 27 labelers | $0.533 per unit 49-51 mg | No current entry |
| Bumetanide | Heart failure | 24 labelers | $0.108 per tablet 1 mg tablet | Resolved |
| Ivabradine | Heart failure | 11 labelers | $0.761 per tablet 5 mg tablet | A presentation being discontinued |
| Eplerenone | Heart failure | 9 labelers | $0.308 per tablet 25 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does digoxin compare with medicines for the same use?
7 side-by-side pages set digoxin beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to digoxin
- 16 medicines for the same use
- Digoxin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other